–
ArriVent BioPharma, Inc.
Metrics score locked — part of Premium
FY22
FY23
FY24
FY25
FY22 – FY25
(positive)
Change from FY23 to FY25
millions USD
FY22:
FY23:
−55.8
FY24:
−70.2
FY25:
−161
millions USD
FY22:
0
FY23:
–
FY24:
−192
FY25:
−71.2
Change from FY22 to FY25
millions USD
FY22:
170
FY23:
42.9
FY24:
187
FY25:
203
millions USD
FY22:
–
FY23:
−13.0
FY24:
−76.1
FY25:
−28.8
All amounts in millions USD FY22: figures supplemented from Twelve Data because the SEC filings do not reach back this far.